Substance / Medication

Fludrocortisone acetate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Effect of fludrocortisone acetate on reducing serum potassium levels in patients with end-stage renal disease undergoing haemodialysis.
Kim Dong-Min, Chung Jong Hoon, Yoon Sung Ho et al. · Nephrol Dial Transplant · 2007
PMID: 17616536RCT
Posterior subcapsular cataract in association with fludrocortisone acetate therapy.
Whyte Ian M, Prior Felicity H, Emslie Ian K et al. · Clin Exp Ophthalmol · 2014
PMID: 24641708Case Report
Hypersensitivity to fludrocortisone acetate in a recipient of bone marrow transplantation.
Kato Jun, Mori Takehiko, Kamo Mariko et al. · Allergol Int · 2011
PMID: 21681020Case Report
Effect of fludrocortisone acetate on chronic unexplained nausea and abdominal pain in children with orthostatic intolerance.
Fortunato John E, Wagoner Ashley L, Harbinson Rachel L et al. · J Pediatr Gastroenterol Nutr · 2014
PMID: 25222805Other
Poly(epsilon-caprolactone) and Eudragit microparticles containing fludrocortisone acetate.
Gibaud Stéphane, Jabir Al Awwadi Najim, Ducki Camille et al. · Int J Pharm · 2004
PMID: 14706260Other
Astaxanthin protects fludrocortisone acetate-induced cardiac injury by attenuating oxidative stress, fibrosis, and inflammation through TGF-β/Smad signaling pathway.
Sarker Manoneeta, Chowdhury Nowreen, Bristy Anika Tabassum et al. · Biomed Pharmacother · 2024
PMID: 39586138Preclinical
Corticosteroid Fludrocortisone Acetate Targets Multiple End Points in Zebrafish (Danio rerio) at Low Concentrations.
Zhao Yanbin, Zhang Kun, Fent Karl · Environ Sci Technol · 2016
PMID: 27618422Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Fludrocortisone acetate (substance)
SNOMED CT
116587006
UMLS CUI
C0616274

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.